ADVERTISEMENT
Gland Pharma Q2 Review — Motilal Oswal Hikes Target Price Post Inline Revenue; Maintains 'Buy'
Niche approval to be near-term key to revive Gland Pharma's growth, profitability, adds Motilal Oswal.
04 Nov 2025, 10:04 AM IST 
Save
Gland Pharma is implementing a two-pronged strategy in GLP-1 opportunity. (Photo Source: Gland Pharma website).
Gland Pharma delivered in-line revenue in Q2 FY26. However, Ebitda/PAT came in below brokerage's expectations by 9%/11%. A lower than-expected share of milestone income and lower tech transfer/contract manufacturing organisation business in rest of world markets impacted Q2 FY26 performance.
